热门资讯> 正文
Allarity Therapeutics开始招募开发Senoparib的II期试验
2026-02-03 21:09
- This is the first trial combining Allarity's stenoparib with another anti-cancer agent
- Stenoparib's favorable safety profile supports potential for use in combination regimens
- Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。